The Medical Advisor

Here’s a concise and evidence-based overview of Ivermectin, Fenbendazole, Mebendazole, and their potential relationship to Multiple Myeloma (MM), a cancer of plasma cells, as of March 26, 2025. This response draws on recent studies and anecdotal reports while acknowledging the current limitations of the evidence. Ivermectin and Multiple Myeloma Ivermectin, an FDA-approved antiparasitic drug, has shown preclinical promise against MM: 2024 Study (Yang Song et al.) : Published in World Journal of Clinical Oncology , this study assessed Ivermectin’s potential against the high-risk t(4;14) MM subtype. Using bioinformatics, molecular docking, and in vitro experiments, it found Ivermectin inhibited MM cell growth and induced apoptosis via the NF-κB signaling pathway. Key genes linked to this subtype were identified, suggesting Ivermectin as a candidate for repurposing. 2023 Study (PubMed) : Ivermectin synergized with proteasome inhibitors (e.g., bortezomib) in vitro and in vivo, inhibiting p...

Abstract Background: Advanced prostate cancer, including metastatic hormone-sensitive and castration-resistant forms, often develops resistance to standard androgen deprivation therapies, highlighting the need for novel adjunctive strategies. Repurposed antiparasitic agents such as fenbendazole and ivermectin have garnered attention for their potential anticancer properties, supported by preclinical studies demonstrating microtubule disruption, apoptosis induction, and metastasis inhibition. Methods: This compilation reviews 64 case reports from 2024–2026, sourced from peer-reviewed publications, social media platforms, and personal testimonials. Protocols typically involved fenbendazole (222–2000 mg/day) and ivermectin (1–2 mg/kg/day), often combined with adjuncts li...